Correction: Iodide Protects Heart Tissue from Reperfusion Injury
Akiko Iwata, Michael L. Morrison, Mark B. Roth
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCardiac Arrest and Resuscitation · Cardiac Ischemia and Reperfusion
The authors wish to amend the Competing Interests statement for this article, which should have included additional information in relation to potential competing interests relevant to this work. The authors apologize for this omission and revise the Competing Interests statement to read as below.
The authors have read PLOS ONE's competing interests policy, and they have the following to declare: Dr. Roth is President, Founder, and a member of the Board of Directors for Faraday Pharmaceuticals, a company dedicated to promoting iodide therapy for ischemic injury. Dr. Roth and his co-authors, Drs. Iwata and Morrison, own stock in the company. Additionally, the authors are named on pending patent applications for iodide therapy (Use of Halogen Compounds For the Treatment and Prevention of Heart Attack and Ischemic Injury). This does not affect or alter our adherence to all of PLOS ONE's policies on sharing data and materials.
The reference list from the paper itself. Each links out to its DOI / PubMed record.